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GeneticsLevels of high-density lipoprotein cholesterol (HDL-C) are inversely related to cardiovascular disease risk
and HDL particles possess a variety of anti-atherosclerotic properties. However, several recent clinical tri-
als aimed at raising HDL-C levels have failed to yield the expected improvement in clinical outcomes,
highlighting the need for a better understanding of HDL particle function and metabolism. Human
genetic studies have proven to be an outstanding source of insight regarding the biology of this complex
lipoprotein class. In particular, the study of rare genetic disorders of HDL has identiﬁed a number of key
players in HDL metabolism, some of which represent current or future therapeutic targets. More recently,
genetic association studies have identiﬁed a large number of additional genes and proteins involved in
HDL metabolism. The purpose of this review is to summarize progress in the study of HDL genetics
and how these insights have contributed to our understanding of the metabolic pathways and function
of HDL leading to opportunities for the long-elusive HDL-based therapies.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
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Plasma levels of high-density lipoprotein cholesterol (HDL-C)
are inversely related to risk of atherosclerotic cardiovascular
disease (CVD). Indeed, among patients with premature CVD, low
HDL-C is the most common lipid abnormality [1]. Compared to ele-
vated levels of low-density lipoprotein cholesterol (LDL-C), HDL-C
is a signiﬁcantly stronger predictor of CVD risk [2]. These epidemi-
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ing HDL-C to reduce CVD risk.
However, several recent clinical trials using various strategies to
raise HDL-C have failed to show the expected improvement in CVD
events [3–8] and Mendelian randomization studies have suggested
that certain genetic variants associated with increases in HDL-C are
not correlated with a reduction in CVD risk [9–11]. The cumulative
effect of these ﬁndings has been to cast doubt on the ‘‘HDL hypoth-
esis’’ [12] that states that decreased plasma HDL concentrations
will lead to impaired reverse cholesterol transport (RCT) and there-
fore accelerated atherosclerosis [13].
Nonetheless, a large body of experimental data has established
that HDL particles do possess anti-atherosclerotic properties
[14,15] and intense interest remains in the prospect of HDL-based
therapeutics to prevent and reverse CVD. What has become clear is
that our understanding of HDL metabolism and function is inade-
quate. Human genetics has been, and remains, one of the primary
means by which we have gained insight into lipoprotein metabo-
lism and function. Here, aspects of HDL human genetics as it
relates to improving our understanding of HDL particle metabo-
lism and function are reviewed.
2. HDL particles and HDL cholesterol
Because it is insoluble in water, cholesterol must be transported
through the circulation in lipoproteins, macromolecules consisting
of an amphipathic lipid monolayer covering a core of hydrophobic
lipids. In humans the major lipoproteins can be separated by ultra-
centrifugation and electrophoretic mobility. Each class of lipopro-
tein contains characteristic apolipoproteins in the lipid
monolayer that direct their transport and function.
HDL particles are a heterogeneous population of lipoproteins,
deﬁned by the density range 1.063–1.21 g/ml. HDL2 and HDL3
are the major forms in human plasma [16]. HDL4 is identical to
newly secreted apo-AI—phospholipid particles, and is also called
nascent HDL, lipid-poor HDL, or pre-b HDL. As the pre-b particle
acquires lipid and undergoes esteriﬁcation it increases in size
and decreases in density to HDL3, HDL2 and HDL1 (the a particles).
An important distinction is between the plasma concentration of
cholesterol present in HDL (HDL-C), and other measures of HDL
particle number, composition or function. In this review the term
‘HDL-C’ is used to refer speciﬁcally to the plasma HDL cholesterol
concentration, and the term ‘HDL’ to refer more broadly to other
aspects of these particles.
3. Monogenic disorders of HDL metabolism
Heritability estimates for HDL-C based on twin studies suggest
that 62–77% of the variance in HDL-C is due to genetic factors [17–
20]. The history of the study of HDL metabolism, and indeed of
lipoprotein metabolism in general, is a testament to the utility of
studying rare genetic diseases in order to gain insight into funda-
mental biological processes. While in many cases, mutations in
genes that cause abnormalities of HDL were identiﬁed based on
prior knowledge of the protein, in virtually all cases the identiﬁca-
tion and study of patients with genetic disorders of HDL has pro-
vided otherwise inaccessible knowledge of the physiological role
of these proteins in human metabolism. Below, knowledge of key
disorders of HDL in humans is summarized, and how identiﬁcation
of the molecular genetics of these conditions has advanced our
understanding of HDL biology.
3.1. ApoA-I
Apolipoprotein A-I (apoA-I), the principal protein constituent of
HDL, is synthesized and secreted by the liver and intestine [21,22].Genetic deﬁciency of apoA-I was ﬁrst reported by Norum and col-
leagues in two sisters with extremely low HDL-C levels and prema-
ture CVD [23]. This established apoA-I as essential for the
biogenesis of HDL particles. Concentrations of other lipoprotein
classes, in particular LDL-C, are not signiﬁcantly altered in apoA-I
deﬁciency.
Individuals who are homozygous or compound heterozygous
for mutations in the APOA1 gene have near complete absence of
apoA-I and HDL-C in plasma. These patients may develop corneal
opacities or xanthomas [24] and are reported to have increased risk
for premature CVD [25]. Heterozygotes for APOA1 deﬁciency have
50% of normal plasma apoA-I and HDL-C levels and generally
do not display peripheral stigmata. Heterozygous mutations in
the APOA1 gene are a rare cause of low HDL-C in the general pop-
ulation [26]. Forty-three mutations have been reported in the
APOA1 gene to-date that cause low HDL-C or low plasma apoA-I
levels [27]. Some mutations have been associated with increased
CVD risk [28]. Carriers of one variant, p.R197C (apoA-IMilano), have
substantially reduced HDL-C levels [29] but are apparently not at
increased risk of CVD, giving rise to the concept that this may be
a beneﬁcial variant [30].
Speciﬁc mutations in APOA1, many of which are in the amino
terminus of the encoded protein, also cause hereditary amyloidosis
that is inherited in an autosomal dominant manner. In contrast to
loss-of-function mutations in APOA1 that lead to low HDL-C, it has
been suggested that amyloidogenic mutations in APOA1 are gain-
of-function variants [31]. Levels of plasma lipoproteins in these
patients can be reduced or normal [32] suggesting that these muta-
tions do not universally interfere with the assembly of HDL.
ApoA-I plays a key structural role in HDL particles, which
contain 2–5 molecules of apoA-I per particle [33]. In addition
to its critical role in HDL assembly, apoA-I also contributes to
the anti-atherosclerotic properties of HDL. Most importantly,
lipid-free apoA-I mediates cholesterol efﬂux by the ATP binding
cassette transporter, sub-family A, member 1 (ABCA1), thus con-
tributing to the RCT pathway. In mice, overexpression of apoA-I
increases macrophage-speciﬁc RCT [34] and decreases athero-
sclerosis [15].
Modiﬁcation of apoA-I contributes to the dynamic and hetero-
geneous nature of HDL, particularly in disease states. HDL has long
been known to have anti-inﬂammatory properties, and in some
studies the anti-inﬂammatory functions of HDL are a better dis-
criminator of CVD status than the HDL-C level [35]. Intriguingly,
during the acute inﬂammatory response, HDL changes from an
anti-inﬂammatory to a pro-inﬂammatory state [36]. Part of this
transition of HDL appears to involve modiﬁcation of apoA-I.
ApoA-I is oxidized by myeloperoxidase in vivo, and this leads to
both the acquisition of pro-inﬂammatory properties [37] and an
impairment in its ability to elicit cholesterol efﬂux [38]. Recently,
a dysfunctional, lipid-poor form of apoA-I in which tryptophan at
residue 72 is oxidized was shown to be a major constituent of
human atherosclerotic lesions [39]. Modiﬁcation of apoA-I leading
to its functional impairment, therefore, appears to be a critical step
in the pathogenesis of atherosclerosis.
3.2. ABCA1
During or soon after its release into plasma, apoA-I particles
acquire lipids in a process dependent on the action of the ABCA1
transporter. Mutations in the ABCA1 gene result in Tangier Disease
(TD) [40–43], an autosomal recessive disorder that was ﬁrst recog-
nized in the Chesapeake Bay area of the United States of America
by Donald Fredrickson [44] and which presents clinically as a near
absence of HDL-C, reduced LDL-C, and yellow lipid-engorged ton-
sils [45,46]. Splenomegaly and consumptive thrombocytopenia
are also frequently present.
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pre-b HDL, with no a-migrating particles [47]. Other clinical man-
ifestations include histiocyte accumulation in the rectal mucosa
and a multifocal demyelinating or syringomyelia-type neuropathy
[48–52]. The demyelinating type neuropathy is characterized mor-
phologically by peripheral nerve demyelination and remyelination,
with lipid vacuoles in Schwann cells [53–55]. The syringomyelia
type, in contrast, is notable for neuronal lipid inclusions and loss
of motor neurons [56]. In clinical practice, neuropathy is often
the presenting symptom of patients with Tangier disease. Some,
but not all studies, have also suggested that TD patients and het-
erozygous carriers of ABCA1 mutations have abnormalities of glu-
cose metabolism [57–60]. Most reports suggest that patients
with TD have increased CVD risk, although not as great as would
be expected based on the extremely low levels of HDL-C [61,62].
Whether heterozygous mutations in ABCA1 increase the suscepti-
bility to atherosclerosis in humans remains the subject of debate
[63–69].
Studies in cultured ﬁbroblasts from patients with TD identiﬁed
the cellular defect in this disorder as an inability to efﬂux choles-
terol and phospholipids in response to apoA-I [70]. This biochem-
ical defect readily explains many of the cardinal clinical
manifestations observed in TD. By failing to efﬂux cholesterol to
apoA-I, HDL particles are either not formed or are unable to
mature, leading to their rapid clearance from the circulation. In
addition, because of the defective efﬂux of cholesterol, cells
become engorged with lipids, leading to the characteristic orange
tonsils, hepatosplenomegaly, and peripheral neuropathy.
Tangier disease was reported in 70 patients prior to the dis-
covery of ABCA1 [71] and molecularly-conﬁrmed TD has been
reported in an additional 100 patients worldwide since thenFig. 1. Model of HDL metabolism as determined by human genetics. ApoA-I is secreted
cellular manner to phospholipidate the newly secreted apoA-I to generate pre-b HDL. AB
discoidal HDL particle that is rich in free cholesterol. LCAT acts to esterify free cholester
spherical HDL. Cholesterol ester transfer protein (CETP) mediates the exchange of CE f
triglyceride rich lipoproteins (TRLs). HDL particles are taken up in the liver by the scaven
from other lipoprotein classes to add to HDL. HDL particles also undergo remodeling b
lipoprotein lipase (LPL, not shown). Sphingosine-1 phosphate (S1P), which may mediat
small HDL that contain apolipoprotein M (apoM).[40–43,52,55,59,72–115], making this an ultra-rare disease. How-
ever, the incidence of TD is likely to be substantially
underestimated.
In addition to causing Tangier disease in the homozygous or
compound heterozygous state, heterozygous mutations in ABCA1
are a common cause of low HDL-C in the general population.
Several studies have investigated the frequency of rare muta-
tions in ABCA1 in individuals with low HDL-C (less than the
5th–10th percentile). Collectively, these studies have reported
that rare variants in ABCA1 can be detected in 5–21.4% (weighted
mean 11.4%) of individuals with low HDL-C [75,116–122]. The
proportion of individuals in whom a mutation can be identiﬁed
is increased if only patients with a family history of low HDL-
C are considered [122].
One-hundred and seventy-seven ABCA1 variants are catalogued
in the Human Gene Mutation Database [27] and these are associ-
ated with a broad range of biochemical and clinical phenotypes
[123,124]. Only some of these variants are pathogenic mutations.
In particular, many variants detected in sequencing studies of
patients with low HDL-C have not been proven to be pathogenic
and the evolutionary conservation of the sites at which these vari-
ants occur is distinct from conﬁrmed pathogenic mutations in
ABCA1 [125].
The effect of mutations in ABCA1 appears to be dominant to
mutations in other HDL-related genes. For instance, even in
patients with mutations in SCARB1 or LIPG who are expected to
have high HDL-C, the presence of a mutation in ABCA1 results in
low HDL-C [126,127]. This is readily explained by the fact that
ABCA1 acts in a very proximal step in HDL biogenesis (Fig. 1),
and the effects of mutations in genes that act downstream of
ABCA1 will generally be masked by mutations in ABCA1.by the liver and intestine. ABCA1 in the liver and intestine acts in an intra- or peri-
CA1 in other tissues, including adipose, acts to add further cholesterol resulting an a
ol to cholesteryl esters (CE) which partition to the core of the particle resulting in a
or triglyceride (TG) between HDL and apoB-containing lipoproteins, including the
ger receptor BI (SR-BI). Phospholipid transfer protein (PLTP) liberates phospholipids
y a variety of lipases including hepatic lipase (LIPG), endothelial lipase (LIPC) and
e some of the atheroprotective properties of HDL, is transported predominantly by
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features, namely near absence of plasma HDL-C and inability to
generate HDL particles, there are also notable clinical differences
between these two disorders. In particular, the systemic manifes-
tations of Tangier disease, including hepatosplenomegaly, periphe-
ral neuropathy and abnormal glucose metabolism are notably
absent in patients with apoA-I deﬁciency. This suggests that it is
the lack of ABCA1-mediated cholesterol efﬂux activity, rather than
the absence of HDL per se, that is responsible for the multi-organ
system involvement in Tangier disease. Indeed, whereas APOA1
gene expression is limited to the liver and intestine, ABCA1 is
widely expressed throughout the body [128] suggesting that it
may play other physiological roles.
Until recently, the speciﬁc role of ABCA1 in discrete tissues was
unknown. Recently, studies using mice with tissue-speciﬁc inacti-
vation of Abca1 have enhanced our understanding of its function in
various organs. Although macrophages are important sites of lipid
accumulation in TD, deletion of Abca1 in macrophages does not
impact HDL-C [129,130] indicating that the macrophage does not
make a quantitatively important contribution to steady-state
HDL-C levels. In contrast, deletion of Abca1 in liver, where it is par-
ticularly abundant [128], leads to a 80% reduction in HDL-C [131]
while deletion of Abca1 in the small intestine leads to 30% reduc-
tion in HDL-C [132]. These studies establish the liver and intestine
as the key sites for HDL biogenesis in vivo.
In pancreatic islets, ABCA1 is essential to prevent cholesterol
overload. Deletion of Abca1 speciﬁcally in beta-cells in mice leads
to cholesterol engorgement, defective exocytosis of insulin-con-
taining granules, and impaired glucose tolerance [133,134]. ABCA1
also plays a key role in brain cholesterol homeostasis, and absence
of Abca1 in the central nervous system leads to increased uptake of
cholesterol by the brain from plasma and abnormalities in neuro-
nal structure and function [135]. ABCA1 in adipose tissues is also
critical for efﬂux of cholesterol to apoA-I and generation of HDL,
and deletion of Abca1 in adipose tissue leads to reduced HDL-C
and abnormal adipose lipid and glucose metabolism [136,137].
These data have established that ABCA1 plays multiple roles in dif-
ferent tissues to maintain cellular cholesterol homeostasis and
inﬂuence a variety of physiological functions.
While hepatic ABCA1 is required for HDL biogenesis [131], stud-
ies in mice have shown that it is not in itself sufﬁcient to generate
mature HDL particles. Reconstitution of Abca1 total body knockout
animals with only hepatic Abca1 leads to a rise in HDL-C lower
than reconstitution of hepatic Abca1 in liver speciﬁc knock-out
mice, and results in smaller HDL particles that are selectively
depleted in free cholesterol and cholesteryl ester (CE) [138]. In
addition, HDL-C levels can be normalized in liver speciﬁc, but not
total body knock-out animals by infusion of reconstituted apoA-I/
phospholipid particles. These data indicate a crucial role for extra-
hepatic Abca1 in contributing cholesterol to HDL particles. A model
that emerges is that hepatic and likely intestinal ABCA1 are essen-
tial for the initial phospholipidation of apoA-I to generate early
pre-b HDL particles (Fig. 1). Some amount of pre-b HDL may also
be made in an ABCA1-independent manner, as small amounts of
this particle are detectable in patients with Tangier disease [47].
After entering the circulation, these particles acquire additional
cholesterol by the action of ABCA1 (and possibly other mecha-
nisms) in other tissues such as adipose tissue. This also explains
the greater-than-additive percent reduction in HDL-C observed in
animals with tissue-speciﬁc inactivation of Abca1 (80% in mice
with liver-speciﬁc deletion of Abca1, 30% in intestinal-speciﬁc dele-
tion, 27% in brain-speciﬁc deletion and 15% in adipose-speciﬁc
deletion) [130–132,135,136]. Deletion of Abca1 in liver or intestine
results in reduced HDL-C because of an inability to generate phos-
pholipidated pre-b particles, whereas deletion of Abca1 in other tis-
sues disrupts the ABCA1-mediated transfer of cholesterol to theseparticles. ABCA1 therefore plays discrete and inter-dependent roles
in different tissues to generate and maintain HDL.
3.3. LCAT
The small HDL particles generated by the actions of ABCA1 in
both hepatic and extrahepatic tissues undergo further maturation
by the action of a secreted enzyme, lecithin:cholesterol acyltrans-
ferase (LCAT). LCAT is secreted predominantly by the liver and cir-
culates in plasma bound to HDL and LDL, where it catalyzes the
esteriﬁcation of free cholesterol to CE and lysophosphatidylcho-
line. Two human genetic diseases are caused by mutations in LCAT,
both inherited as autosomal recessive traits.
Severe mutations in LCAT leading to complete loss of enzymatic
activity cause Familial LCAT Deﬁciency (FLD), ﬁrst reported in the
1960s [139]. Milder mutations in LCAT in which enzyme activity
against HDL is lost but is retained against other lipoprotein parti-
cles results in Fish Eye Disease (FED), so-called because of the
appearance of the eyes of these patients [140]. Patients with FLD
present with corneal opacities, lipemia, anemia, proteinuria and
renal failure that can progress to end-stage renal disease [141].
The pathogenesis of renal failure in these patients is not well
understood but it is thought to be related to the presence of an
abnormal free cholesterol and phospholipid-rich particle termed
lipoprotein X (LpX) that accumulates in the renal glomeruli
[142,143]. In support of this concept, a transgenic mouse model
that selectively accumulates LpX develops spontaneous glomeru-
lopathy [144]. The anemia of FLD is typically mild, normocytic,
and is thought to result from increased hemolysis and decreased
erythropoiesis [145].
The most striking lipoprotein abnormality in FLD is a 70–80%
reduction in plasma HDL-C and apoA-I [146]. Plasma LDL-C, cho-
lesterol ester and lysophosphatidylcholine concentrations are also
markedly reduced while plasma levels of free cholesterol are
increased. The distribution of residual HDL in patients with FLD
is shifted towards smaller particles, predominantly those with
pre-b mobility and some smaller a-migrating particles [146]. This
indicates that LCAT is not essential for the formation of pre-b HDL
but is required for the generation of mature, larger spherical parti-
cles. In FED, patients develop corneal opacities and low HDL-C but
without the anemia or renal disease observed in FLD.
The esteriﬁcation of free cholesterol in HDL is necessary to par-
tition CE to the centre of the maturing HDL particle and to maintain
a gradient of free cholesterol between cells and HDL particles, thus
allowing the continued efﬂux of cholesterol from peripheral cells
to HDL. Indeed, the existence of a physiologically signiﬁcant
plasma cholesterol esteriﬁcation reaction was the initial basis on
which Glomset postulated the RCT hypothesis, in which choles-
terol can be returned by HDL from peripheral tissues to the liver
[147].
Whether patients with LCAT deﬁciency have accelerated athero-
sclerosis is controversial [140,148,149] and these patients display
substantial phenotypic variability [150]. Some, but not all, imaging
studies have reported increased atherosclerosis in heterozygous
carriers of LCAT mutations [151–153]. Recently, it was reported
that patients with LCAT mutations and very low HDL-C (<5th per-
centile for age and gender) have increased CVD risk compared to
ﬁrst-degree relative controls, raising the possibility that LCAT deﬁ-
ciency may impact atherogenesis in patients with the most signif-
icant reduction in HDL-C [122].
FLD and FED are rare disorders, but mutations in LCAT occur fre-
quently in patients with low HDL-C in the general population. In
one recent study of Dutch and Canadian probands with low HDL-
C (less than the 10th percentile for age and gender), 15.7% had a
mutation in LCAT [122]. Moreover, when only probands with at
least one ﬁrst-degree relative with low HDL-C were considered,
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tions, LCATmutations have been identiﬁed in 2.4–25.6% of patients
with low HDL-C [75,119,120,154], with the highest frequency
observed in the Dutch population. While the functional signiﬁ-
cance of many of these mutations remains uncertain, these data
indicate that, in addition to being the cause of the rare Mendelian
disorders, FLD and FED, LCATmutations are a common cause of low
HDL-C in the general population, particularly in certain ethnic
populations.
3.4. CETP
Cholesterol in HDL can be returned to the liver via two mecha-
nisms, the direct RCT pathway in which HDL-containing choles-
terol is taken up by the liver by HDL receptors, and the indirect
reverse cholesterol transport pathway, in which cholesterol is ﬁrst
transferred to an apoB-containing lipoproteins for hepatic uptake
via LDL receptors. Cholesterol ester transfer protein (CETP) medi-
ates the equimolar transfer of CE from HDL for TG from LDL, VLDL
or chylomicrons. Human deﬁciency of CETP was ﬁrst reported in
ﬁve Japanese families with a common splice mutation in intron
14 [155,156]. Individuals homozygous for CETP mutations have
markedly elevated HDL-C and apoA-I levels. The catabolism of
HDL apolipoproteins is reduced in these patients while their pro-
duction rate is unchanged [157], indicating that CETP-mediated
transfer of CE de-stabilizes HDL particles and increases their catab-
olism by the kidney. Patients with CETP deﬁciency also have 35%
reduction in LDL-C [156], and LDL from these patients undergoes
rapid catabolism [158]. Similar changes in LDL-C are observed in
patients receiving potent pharmacologic CETP inhibitors [159].
The two most common mutations in CETP are the originally
described intron 14 splice variant (c.1321+1G>A, rs5742907) as
well as a missense variant, p.D449G (rs2303790). The frequency
of these mutations is highly variable in different ethnic groups.
p.D449G is present in 2–3% of Japanese and Chinese individuals,
but is absent in Europeans (www.1000genomes.org). Similarly,
c.1321+1G>A is found in 1% of Japanese but is not observed in
other populations. The prevalence of CETP deﬁciency has been
reported to be extremely high in some regions of Japan [160,161].
The relationship between CETP and atherosclerosis remains
hotly contested. Early reports suggested that CETP deﬁciency in
humans was associated with longevity and resistance to athero-
sclerosis [156]. However, this ﬁnding has not been consistently
borne out in subsequent studies [162–165]. In addition, the two
CETP inhibitors that have been evaluated in phase 3 clinical end-
point trials, torcetrapib and dalcetrapib, have failed to show reduc-
tions in CVD endpoints despite signiﬁcant elevations in HDL-C
[3,4]. Two additional CETP inhibitors, evacetrapib and anacetrapib,
are currently being evaluated in clinical trials.
It seems likely that deﬁciency or inhibition of CETP results in a
combination of pro- and anti-atherogenic effects. The increase in
HDL-C concentration, HDL particle size and number is likely to lead
to enhanced ability of HDL to promote the vasodilatory, cytopro-
tective and anti-diabetic effects of HDL – properties that associate
with the abundance of HDL in the circulation. Indeed, treatment
with torcetrapib improves glucose tolerance and islet function
[166]. Simultaneously, CETP inhibition or deﬁciency blocks the
indirect pathway of RCT, in which CE are transported by CETP from
HDL to apoB-containing lipoproteins and subsequently cleared
from the circulation by LDLR-mediated particle uptake, thereby
decreasing ﬂux through the HDL pathway. Whether genetic or
pharmacologic depletion of CETP is pro- or anti-atherogenic in a
given individual will likely depend on which of these two sets of
functions is most critical for atherogenesis, which may in turn vary
from person to person based on their genomic or environmental
background and threshold for plaque formation.3.5. Lipases: LPL, LIPC and LIPG
The CE depletion and TG enrichment of HDL by CETP primes the
particle for hydrolysis by lipase enzymes. HDL particles undergo
extensive remodeling in the vascular compartment by several
extracellular lipases that display distinct substrate speciﬁcities.
Three lipases are known to play roles in remodeling HDL in
humans, lipoprotein lipase (encoded by the LPL gene), hepatic
lipase (encoded by LIPC) and endothelial lipase (encoded by LIPG).
Human genetic syndromes associated with mutations in each of
these three genes have been described.
Patients with milky lipemic plasma were recognized as early as
the late 18th century and familial chylomicronemia (Frederickson
hyperlipoproteinemia type 1) was ﬁrst reported in the early 20th
century [167]. This disorder, which manifests as severe hypertri-
glyceridemia, eruptive xanthomas and recurrent pancreatitis, was
subsequently shown to be due to an absence of lipoprotein lipase
activity [168]. The ﬁrst mutations in the LPL gene in familial
chylomicronemia were reported in 1989 [169]. Patients with LPL
deﬁciency also display signiﬁcantly reduced plasma LDL-C and
HDL-C, in particular a near absence of HDL2 and reduced HDL3.
These observations therefore indicate that plasma HDL-C, and in
particularly cholesterol transported by HDL2, are dependent on
the activity of LPL, potentially by LPL releasing apolipoproteins
from chylomicrons and VLDL particles necessary for the generation
and maturation of HDL. These ﬁndings also provide a molecular
underpinning for the known inverse relationship between plasma
TG and HDL levels. Recently, a gene therapy product for LPL deﬁ-
ciency consisting of delivery of the beneﬁcial LPLS447X gene variant
[170] obtained regulatory approval, becoming the ﬁrst approved
gene therapy product in humans [171].
Hepatic lipase, encoded by the LIPC gene, is synthesized in the
liver and secreted into plasma where it acts primarily to hydrolyze
triglycerides in HDL and to a lesser extent phospholipids. Patients
with deﬁciency of hepatic lipase have increased levels of total
plasma cholesterol, triglycerides and HDL-C [172–174]. In particu-
lar, HDL-TGs tend to be increased in these patients. Genetic deﬁ-
ciency of LIPC is a very rare condition, with only 12 pathogenic
mutations reported in this gene [27]. Patients with LIPC deﬁciency
are generally considered to have increased CVD risk despite their
elevated HDL-C [175]. This underscores that not all mechanisms
leading to increased HDL-C are associated with protection from
CVD.
Endothelial lipase is the most recently identiﬁed member of the
lipase family and acts primarily as a phospholipase. Studies in mice
have shown that overexpression of Lipg results in reduced HDL-C
and apoA-I [176]. Inhibition of Lipg activity in mice using an inhib-
itory antibody results in increased HDL-C and slowed catabolism of
HDL-PLs [177]. LIPG-mediated hydrolysis of HDL-PL therefore
appears to facilitate the removal of HDL particles from the circula-
tion. Common genetic variants in the LIPG gene are associated with
HDL-C in humans [178], and rare, loss-of-function coding variants
as well as regulatory variants in LIPG have been reported that
impact HDL-C [179–181]. Carriers of rare, loss-of-function muta-
tions in LIPG have increased HDL-C, and HDL from these patients
has enhanced ability to elicit cholesterol efﬂux from cells [179].
Some studies have suggested that carriers of LIPG loss-of-function
mutations have reduced CVD [179]. In contrast, a large Mendelian
randomization study reported that a variant in LIPG was not asso-
ciated with a decrease in incident myocardial infarction [9].
Several genes impact HDL-C indirectly via altering the activity
of LPL. This includes apolipoprotein C-II, a physiological activator
of LPL. Deﬁciency of APOC2 presents clinically very similarly to
LPL deﬁciency [182]. APOC2 deﬁciency is extremely rare, with only
a handful of patients described with this condition worldwide
[182–191]. ApoC-III is an inhibitor of LPL, and patients with
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C and increased HDL-C [192,193]. Recently, two large studies
reported that patients with these atheroprotective lipid proﬁles
caused by APOC3 mutations have reduced CVD risk [194,195],
sparking interest in APOC3 as a potential therapeutic target.
ApoC-III is glycosylated by the GALNT2 gene product, and loss-
of-function mutations in GALNT2 result in impaired ability of
apoC-III to inhibit LPL [196]. Carriers of mutations in GALNT2 have
elevated HDL-C and reduced TG [127,196]. Based on the observed
reduction of CVD risk in patients with mutations in APOC3
[194,195], carriers of mutations in GALNT2 would also be expected
to have reduced CVD risk. However, the impact of GALNT2 muta-
tions on CVD risk in humans has not been evaluated.3.6. PLTP
Whereas CETP mediates the transfer of CE from and triglycer-
ides to HDL, phospholipid transfer protein (PLTP) is involved in
the transfer of phospholipids from apoB-containing lipoproteins
to HDL in a process that is essential for HDL maturation and main-
tenance. Mice lacking Pltp display markedly reduced HDL-C and
phospholipids levels and reduced plasma apoA-I concentrations
[197]. In humans, candidate gene studies have identiﬁed genetic
variants in PLTP that are associated with both high and low HDL-
C, [119,198,199], and some of these variants lead to reduced PLTP
function. A role for PLTP in inﬂuencing HDL-C levels in humans has
also been highlighted by the identiﬁcation of PLTP as a locus for
both TG and HDL-C in genome wide association studies (GWAS)
[200]. One putative loss-of-function mutation in PLTP has been
reported in a patient with ataxia [201]. However, the causal rela-
tionship between that mutation and the phenotype in question is
uncertain. To-date, no rare loss-of-function mutations in PLTP have
been identiﬁed in humans that lead to highly penetrant abnormal-
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Fig. 2. Genetic architecture of HDL-C. Mutations across the entire spectrum of allele
frequencies have been shown to impact HDL-C. Remarkably, these variants occur in
largely the same group of genes. Very rare or private mutations that typically result
in complete inactivation of the gene-product lead to characteristic and highly
penetrant disorders of HDL, such as Tangier disease, Familial LCAT deﬁciency and
apoA-I deﬁciency. These disorders have been uncovered through the study of
families in which these conditions segregate. Sequencing studies have identiﬁed
that rare variants in these same genes, with minor allele frequencies of up to 1%, are
a frequent cause of low HDL-C in the population. Finally genome wide association
studies (GWAS) have identiﬁed that common variants, with allele frequencies up to
50%, and which themselves have little impact of protein function, are statistically
associated with HDL-C levels, although the magnitude of the effect is typically very
small.3.7. SCARB1
HDL particles have long been known to be the preferential
source of plasma cholesterol that ultimately appears in bile
[202]. The identiﬁcation of the scavenger receptor class B mem-
ber I (SR-BI, encoded by the SCARB1 gene) as a high-afﬁnity HDL
receptor in the liver [203] that mediates the selective uptake of
HDL cholesterol but not protein [204] established SR-BI as a
critical mechanism by which HDL-C is taken up by the liver
for removal into bile. Overexpression of hepatic Scarb1 in mice
substantially lowers plasma HDL-C [205], while targeted inacti-
vation of Scarb1 results in increased HDL-C [206]. Notably, mice
lacking Scarb1 have increased susceptibility to atherosclerosis
despite having elevated HDL-C [207], highlighting the impor-
tance of not only the level of HDL-C but the mechanism by
which that level is achieved in determining the impact on
atherosclerosis.
Despite the key role of SR-BI in HDL-C uptake having been
described in 1996 [203] and clear evidence of its physiological role
in mice, validation of the role of SR-BI in human metabolism was
not established until 15 years later when patients with mutations
in SCARB1 were ﬁrst reported [208]. To date, three patients with
deﬁciency of SCARB1 leading to elevated HDL-C have been reported
[126,208]. Functional studies have validated that these represent
loss-of-function mutations [209]. Carriers of these mutations have
elevated HDL-C as well as impaired platelet function and dimin-
ished adrenal function [208]. These studies have therefore estab-
lished the physiological importance of SCARB1 as a hepatic HDL
receptor in humans.4. Common and rare genetic variants and HDL-C
In the pre-GWAS era, several candidate gene studies reported
association of common variants in many of the genes described
above with HDL-C levels in the general population [199,210]. Since
2006, sixteen GWAS have examined the association of common
genetic variants with HDL-C levels (www.genome.gov/gwastud-
ies), culminating in the 2013 Global Lipids Genetics Consortium
Results study of >180,000 individuals [200]. Seventy-one loci that
impact HDL-C were identiﬁed with genome-wide levels of statisti-
cal signiﬁcance, including 46 loci for which the association is
exclusively with HDL-C (with no statistically signiﬁcant associa-
tion to other lipid parameters). Perhaps one of the most remark-
able ﬁndings to emerge from these studies has been the
re-identiﬁcation of many genes previously known to impact HDL
metabolism, including ABCA1, APOA1, LIPG, LIPC, PLTP, LPL and
SCARB1, thus validating the important role of common variation
at these loci inﬂuencing HDL-C levels in the general population.
Many of the 46 loci associated exclusively with HDL-C have no
prior knowledge of their involvement in HDL metabolism. Already,
some of these loci have been validated in terms of their role in HDL
metabolism in humans [127,196,211]. For instance, GALNT2, a gene
ﬁrst identiﬁed in GWAS [212], has been identiﬁed to play a role in
glycosylation of apoC-III, an inhibitor of LPL [196]. Loss of GALNT2
function would therefore lead to impaired ability of apoC-III to
inhibit LPL, leading to increased HDL-C. In addition, rare variants
that are predicted to impair function in GCKR, LILRA3 and DNAH10,
all genes previously implicated in HDL-C levels by GWAS
[212,213], were recently shown to segregate in families with high
HDL-C [214] providing strong evidence for an important role of
these genes in HDL metabolism. However, for the most part the
role of gene products at these GWAS loci in human HDL metabo-
lism remains unclear. In particular, how these various gene prod-
ucts overlay the established model of HDL metabolism (Fig. 1) is
uncertain. Deciphering the biological and physiological role of
these gene products in lipid metabolism remains an exciting
challenge.
More recently, sequencing and ‘‘exome-chip’’ studies have exam-
ined the contribution of rare variants to HDL-C levels. In a study of
6000 individuals from the Finnish population, re-sequencing of
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(MAF) <1% in ABCA1 that were associated with HDL-C and TC, using
both single variant and gene-level tests of association [215]. Most of
these variants were associated with decreased HDL-C and total cho-
lesterol, suggesting that they act as loss-of-function variants. Eight
variants in ABCA1 were predicted to be ‘‘probably damaging’’, and
these alleles ranged in frequency from singletons to a MAF of 0.2%
for the missense variant P85L, a variant previously implicated to
cause low HDL-C in a family with familial low HDL-C [216]. Signiﬁ-
cant associations with HDL-Cwere also observed for rare variants in
CETP, LIPC and LIPG. An exome-chip study involving 42,000 Europe-
ans and 14,000 African Americans identiﬁed rare (MAF 0.24–0.34%)
variants at CETP and LCAT associated with HDL-C [217]. This study
also identiﬁed association with previously unreported loci, ANG-
PTL8, PCSK7 and PAFAH1B2. One whole genome sequencing study
of 962 individuals identiﬁed signiﬁcant associations with HDL-C at
the CETP locus, and a previously unidentiﬁed locus, PARM1 [218].
Emerging from these various studies of HDL genetics is the rec-
ognition that levels of HDL-C are inﬂuenced by genetic variants
across the entire spectrum of allele frequencies and genetic
penetrance, occurring in largely the same group of genes (Fig. 2).
Ultra-rare disorders of HDL, which are typically inherited in an
autosomal recessive pattern and are caused by very rare or private
mutations that inactivate the encoded protein result in highly
penetrant and characteristic phenotypes with major changes in
HDL-C. Heterozygous mutations in these same genes, some of
which occur at frequencies of up to 1% in populations (but usually
less than 0.1–0.2%), are associated both individually and at the
gene-level with HDL-C, and are particularly frequent in individuals
at the extreme ends of the population distribution of HDL-C.
Finally, common variants with frequencies of 1–50% in these same
genes as well as other genes are highly statistically associated with
HDL-C, although individually the magnitude of the effects these
variants exert on HDL-C are minimal, as are the presumed effects
on protein function. HDL-C is therefore paradigmatic as a trait for
which the genetic architecture is determined by the full spectrum
of alleles from private to common variants occurring in a group of
genes.5. Future questions and implications for HDL-based therapies
How can these observations regarding genetic variants impact-
ing HDL metabolism and function be translated into clinical oppor-
tunities to improve the care of patients with disorders of lipid
metabolism and to reduce CVD risk? One important lesson from
the study of rare genetic conditions of HDL that is immediately
apparent is that not all mechanisms that lead to elevated HDL-CTable 1
Genes that modulate HDL-C levels in humans and the impact of mutations in these
genes on cardiovascular disease (CVD) risk.
Gene Effect on HDL-C Effect on CVD
APOA1 ; "
ABCA1 ; "/–
LCAT ; "/–
CETP " ;/–
LPL ; "/–
LPIC " "
LPIG " ;/–
APOC2 ; ND
APOC3 " ;
GALNT2 " ND
PLTP ; ND
SCARB1 " "?
ND, no data available; –, no effect; ?, hypothesized effect based on data from mice.should be predicted to result in reduced CVD risk. Indeed, deﬁ-
ciency of either LIPC or SCARB1 results in elevated HDL-C but not
in protection from CVD (Table 1). This observation is relevant to
the interpretation of Mendelian randomization studies of HDL-C.
One study, which demonstrated that a variant in LIPG, N396S, is
associated with raised HDL-C but not decreased CVD, could be
interpreted as indicating that raised HDL is not cardioprotective
[9]. An alternative interpretation is that not all mechanisms that
lead to raised HDL-C are cardioprotective, a ﬁnding in agreement
with earlier data from monogenic disorders of HDL metabolism.
An ideal therapeutic target would result not only in increased
HDL abundance, but in increased particle functionality and ﬂux
through the pathway. Several HDL-based therapies have been
tested in humans, and in many instances these strategies have
been informed by observations from human genetics. Infusion of
recombinant apoA-IMilano was shown to signiﬁcantly reduce ather-
oma volume as detected by intra-vascular ultrasound after only
5 weeks of treatment [219]. Similarly, infusion of pre-b HDL results
in angiographic improvement of plaque composition [220]. Several
other apoA-I based therapies including transcriptional activators
and mimetic peptides are at various stages of clinical development
[221].
ABCA1 remains an attractive therapeutic target, and studies in
mice would predict that increasing ABCA1 would be expected to
not only raise HDL-C but also protect from atherosclerosis and
improve glucose metabolism [133,222,223]. ABCA1 is strongly
transcriptionally regulated by the liver X receptor (LXR), but agon-
ism of LXR leads to undesirable activation of lipogenic genes in the
liver. Recent progress in modulating ABCA1 expression by targeting
microRNA-33a/b has provided new opportunity to therapeutically
augment ABCA1 expression in vivo [224–228].
Despite the failures of the ﬁrst two CETP inhibitors in late-stage
clinical trials, there remains substantial activity and investment in
this approach to raise HDL-C. Torcetrapib and dalcetrapib may
have failed because of off-target effects and relatively weak CETP
inhibition, respectively. However, there is also reason to suspect
that CETP inhibitors as a class may not result in CVD reduction.
For now, the story of CETP inhibition and CVD remains unresolved
[229]. The results of clinical trials of the potent CETP inhibitors,
anacetrapib and evacetrapib, are anxiously anticipated to help clar-
ify these issues.
As discussed above, mutations in APOC3 lead not only to athero-
protective lipid proﬁles, including elevated HDL-C and reduced TG,
but are associated with reduced CVD risk in humans. This provides
strong human validation of APOC3 as a therapeutic target. A phase
1 trial of an antisense oligonucleotide against APOC3 has been
reported showing dose-dependent reductions in TG with small
increases in HDL-C [230]. One small study of three patients with
homozygous or compound heterozygous mutations in the LPL gene
demonstrated that antisense inhibition of APOC3 lowered TGs by
50–80% [231], providing evidence that APOC3 also participates in
an LPL-independent pathway of TG removal. Whether small mole-
cule inhibitors of APOC3 can be developed that result in beneﬁcial
effects in humans is an unknown but exciting possibility.
Recently, the bioactive lysophospholipid sphingosine-1-phos-
phate (S1P) has received attention as a potential mediator of many
of the atheroprotective properties of HDL [232–234]. S1P is carried
in plasma predominantly by HDL particles where it associates with
apolipoprotein M. One S1P receptor agonist, ﬁngolimod, has been
approved by the FDA for the treatment of multiple sclerosis. In
mice, administration of this compound reduces atherosclerosis
[235] with no change in HDL-C, consistent with the concept that
agonism of the S1P receptor may enhance HDL functionality with-
out a change in HDL-C. However, ﬁngolimod is associated with bra-
dycardia in humans leading to a recommendation to avoid this
agent in patients with a recent history of CVD. Newer S1P receptor
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tors may identify compounds with more favorable safety and phar-
macological proﬁles and lead to opportunities to modulate this
pathway in order to augment HDL function and ameliorate
atherosclerosis.6. Conclusions
HDL are remarkably complex, dynamic and heterogeneous par-
ticles. Human genetics has identiﬁed major proteins involved in
the biogenesis, transport, remodeling and uptake of HDL. Remark-
ably, rare Mendelian diseases have been identiﬁed affecting virtu-
ally every step of the HDL metabolic pathway, and rare and
common variants in these same genes also inﬂuence levels of
HDL-C in the general population. More recent discoveries from
genome-wide approaches have revealed a large number of new
candidate genes that impact HDL-C, but the biological role of these
genes and proteins on HDL remains largely unknown. Elucidation
of their functional roles promises to further expand our knowledge
of HDL biology. Despite the large-scale failures of several attempts
to therapeutically increase HDL-C, there remains substantial inter-
est in the possibility of HDL-based therapeutics to reduce CVD risk
in patients. A better understanding of the pathways of HDL metab-
olism, its cargo, and its relationship to atherogenesis may bring us
closer to this goal.Conﬂict of interest
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